Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity - Additional Information (Details)

v3.21.2
Stockholders' Equity - Additional Information (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jan. 01, 2021
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Jun. 09, 2021
Dec. 31, 2020
Nov. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Common Stock, Shares Authorized   135,000,000   135,000,000   135,000,000 95,000,000  
Common Stock, Increase in authorized shares (in shares)           40,000,000    
Common Stock, Par or Stated Value Per Share   $ 0.0001   $ 0.0001   $ 0.0001 $ 0.0001  
Common Stock, Shares, Issued   75,741,873   75,741,873     62,420,439  
Common Stock, Shares, Outstanding   75,741,873   75,741,873     62,420,439  
Shelf Registration Statement, Maximum Authorized Securities               $ 100,000,000
Issuance of common shares, net of offering costs - At-the-market offering   $ 10,824,000 $ 2,604,000 $ 34,717,000 $ 2,604,000      
Issuance of common shares - Founders Agreement   253,000 $ 66,000 887,000 $ 66,000      
Shelf registration statement remaining authorized securities   60,300,000   60,300,000        
Non-vested Restricted Stock [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Total unrecognized compensation cost related to non-vested   $ 3,800,000   $ 3,800,000        
Weighted average period (in years)       1 year 10 months 24 days        
Performance Shares [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Restricted stock outstanding non-vested   333,334   333,334        
2015 Incentive Plan [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Number of shares available for issuance Authorized     9,000,000   9,000,000      
Plans expires (in years)       10 years        
Shares are available for issuance   3,319,453   3,319,453        
At the Market Offering [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Number of shares sold       10,399,983        
Sale price per share   $ 3.42   $ 3.42        
Gross proceeds from issue of shares       $ 35,600,000        
Net proceeds from the offering       $ 34,700,000        
Stock Issued During Period Shares Common Shares For At The Market Offering       10,399,983        
Stock Issued During Period Value Common Shares For At The Market Offering Gross       $ 35,600,000        
Issuance of common shares, net of offering costs - At-the-market offering       34,700,000        
Commissions and other transaction costs       $ 900,000        
Fortress Biotech, Inc [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Number of shares sold 1,742,449     259,990        
Percentage of annual equity fee 2.50% 2.50%   2.50%        
Issuance of common shares - Founders Agreement       $ 887,000        
Agent [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Commission rate   3.00%   3.00%        
Common Class A [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Common Stock, Shares Authorized           7,000,000    
Common Stock, Shares, Issued   7,000,000   7,000,000     7,000,000  
Common Stock, Shares, Outstanding   7,000,000   7,000,000     7,000,000